审查Entasis Therapeutics（纳斯达克股票代码：ETTX）和Sol-gel Technology（纳斯达克股票代码：SL GL）

Entasis Therapeutics (NASDAQ:ETTX – Get Rating) and Sol-Gel Technologies (NASDAQ:SLGL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Insider and Institutional Ownership

6.9% of Entasis Therapeutics shares are owned by institutional investors. 6.5% of Entasis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Get Entasis Therapeutics alerts:

Profitability

This table compares Entasis Therapeutics and Sol-Gel Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entasis Therapeutics	N/A	-145.48%	-103.75%
Sol-Gel Technologies	28.91%	19.41%	16.45%

Earnings and Valuation

This table compares Entasis Therapeutics and Sol-Gel Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entasis Therapeutics	$7.00 million	14.97	-$47.14 million	($1.12)	-1.96
Sol-Gel Technologies	$31.27 million	3.84	$3.22 million	$0.41	14.37

Sol-Gel Technologies has higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Entasis Therapeutics and Sol-Gel Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entasis Therapeutics	0	4	1	0	2.20
Sol-Gel Technologies	0	0	2	1	3.33

Entasis Therapeutics currently has a consensus price target of $3.53, indicating a potential upside of 61.34%. Sol-Gel Technologies has a consensus price target of $18.33, indicating a potential upside of 211.26%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Entasis Therapeutics.

Risk and Volatility

Entasis Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Summary

Sol-Gel Technologies beats Entasis Therapeutics on 12 of the 15 factors compared between the two stocks.

About Entasis Therapeutics

(Get Rating)

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

About Sol-Gel Technologies

(Get Rating)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.